Abstract: The present invention provides a method for removing unreacted monomer in polymer using a SCC comprising a housing having a rotation axis; a supply part of at least one polymer formed inside of the housing; at least two spinning cones that are installed so as to have a constant gradient from the upper part to the lower part to the rotation axis, move polymer supplied through the polymer supply part, and rotate around the rotation axis; a fixed cone that is fixed and formed on the inner side of the housing, and provides a pathway for sequentially moving polymer from a spinning cone at the upper part to a spinning cone at the lower part; a product collection part for collecting polymer moved through the spinning cone and the fixed cone; and a driving part for rotating the spinning cone.

Abstract: The present invention relates to a process for radically curing a composition comprising a methacrylate containing compound (a1) and a monomer copolymerizable with said methacrylate containing compound in the presence of a 5 transition metal compound (c) and a peroxide, wherein the composition comprises a compound (b) according to formula (1) as monomer copolymerizable with said methacrylate containing compound whereby n=0-3; R1 and R2 each individually represent H, C1-C20 alkyl, C3-C20 cycloalkyl, C6-C20 aryl, C7-C20 alkylaryl or C7-C20 arylalkyl; X=O, S or NR3 whereby R3=H, C1C20 alkyl, C3-C20 cycloalkyl, C6-C20 aryl, C7-C20 alkylaryl, C7-C20 arylalkyl, part of a polymer chain or attached to a polymer chain, and the composition comprises at least one transition metal compound (c) selected from the group consisting of Co, Cu, Mn and Fe compounds, and the curing is effected in the presence of a peroxide selected from the group consisting of hydroperoxides, perketals, peresters, percarbonates and mixtures ther

Abstract: The invention relates to a process for producing water-absorbing polymer particles, comprising thermal postcrosslinking in a contact dryer having external heated outer surfaces.

Abstract: The present invention provides a carboxyl group-containing polymer composition that exhibits excellent anti-soil redeposition ability in fabric washing. The carboxyl group-containing polymer composition contains a carboxyl group-containing polymer, which includes specific ratios of a structure unit (a) derived from an acrylic acid-based monomer (A) and a structure unit (b) derived from a sulfonic acid group-containing monomer (B) and has a specific weight average molecular weight, and a specific amount of an adduct of a hydrogen sulfite to the acrylic acid-based monomer (A).

Abstract: The invention relates to a process for producing water-absorbing polymer particles, comprising polymerization, drying the resulting polymer gel on a through circulation belt dryer, crushing the dried polymer gel, pre-grinding, separating of incompletely dried particles with a perforated plate, grinding and classifying the resulting polymer particles.

Abstract: Group 4 metal complexes comprising a polyvalent, heteroaryl donor ligand and their use as components of olefin polymerization catalysts, especially suited for preparing propylene copolymer products having high isotacticity and low molecular weight, are disclosed.

Abstract: The present invention relates to a process of forming a polymer, the process comprising polymerizing olefin monomers to form a reaction mixture, treating the reaction mixture to form a first polymer-rich phase, treating the first polymer-rich phase to form a second polymer-rich phase, and devolatilizing the second polymer-rich phase, the process further comprising at least one step of adjusting the temperature of a first and/or the second polymer-rich phase before the devolatilization. The present invention also relates to a plant that is useful for the process provided above.

Abstract: The present invention is directed to a novel biocompatible polymer that may be used in tissue engineering. More specifically, the specification describes methods and compositions for making and using citric acid copolymers.

Abstract: In a process for producing polyamides by polycondensation of polycondensable polyamide-forming monomers and/or oligomers in reaction mixtures comprising same, which may be water-containing but are free from organic solvents, the polycondensation is effected in an agitated reactor under agitation in a first step in the liquid phase and after a phase change taking place during the process in the same reactor is effected in a subsequent second step in the solid state, wherein the temperature in the reactor is below the melting point of the polyamide in the second step at least.

Abstract: High molecular weight disulfide polymers are synthesized in aqueous media by exposing dithiol compounds to a mild oxidizing environment in the presence of a tertiary amine catalyst. The unique oxidizing system polymerizes monomers through the formation of sulfur-sulfur bonds between dithiol compounds. The same oxidizing system may be used to make disulfide-crosslinked gels from compounds containing multiple thiol groups. The oxidizing system is comprised of oxygen at atmospheric concentration and dilute hydrogen peroxide. A filler such as carbon black may be incorporated into the polymer or cross-linked gel during polymerization. A polydisulfide polymer is provided having a weight average molecular weight of greater than about 100,000 g/mol and a polydispersity index of about 2 or less. A tetrathiol composition results from a reaction of a diacrylate with a trithiol.

Abstract: To provide a polyimide precursor and/or polyimide which has an excellent solubility in various organic solvents, and with which a liquid crystal alignment film can be obtained which is excellent in a rubbing resistance and which is hardly deteriorated even by irradiation with backlight. A polyimide precursor having its terminal amino group modified with at least one alicyclic epoxydicarboxylic acid anhydride selected from the group consisting of compounds of the formulae [1] and [2], or a polyimide obtained by imidizing it: wherein Y is a C1-2 alkylene or an oxygen atom, and R1 is a hydrogen atom or an organic group represented by —X1—X2—X3 , wherein X1 is a single bond or —CH2—, X2 is a single bond or -0-, and X3 is a C1-20 alkyl group, a C1-20 haloalkyl group or a C1-20 alkyl group containing a cyano group.

Abstract: The present disclosure is directed, in part, to methods of synthesizing a poly(ethylene carbonate) polymer from the reaction of ethylene oxide (EO) and carbon dioxide (CO2) in the presence of a metal complex. The present disclosure also provides novel metal complexes. In one aspect, the metal complex is of the formula (I), wherein R1, R2, R3, M, X and Ring A are as defined herein.

Abstract: The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function.

Abstract: The invention described herein pertains to an improved process for preparing the folate-targeted conjugate EC145 and to the conjugate EC145 prepared using the improved process, as well as to a pharmaceutical composition comprising the conjugate EC145 prepared using the improved process.

Abstract: Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin receptor binding ligands. The conjugates also include a releasable bivalent linker.

Abstract: Cell-free extracts, methods for producing these extracts, methods for using these extracts, compositions that facilitate production of these extracts and kits that contain these extracts are provided. By increasing or decreasing certain gene products through, for example, the use of siRNA or mimics, one can develop mammalian cell-free extracts that have desired levels of efficiency.

Abstract: A method for separating proteins and fats from an egg mixture is disclosed herein. The method includes a step of microfiltration of the egg mixture, wherein microfiltration includes pumping across a filter an egg mixture containing egg yolk and egg whites (albumen). An egg powder obtained from egg and a high gel strength egg powder are also disclosed.

Abstract: A canola protein isolate useful in aquaculture is formed by a procedure in which canola oil seed meal is extracted to cause solubilization of protein in the canola oil seed meal to form an aqueous protein solution having a protein content of about 5 to about 40 g/L and a pH of about 5 to about 6.8. After separation of the aqueous protein solution from the residual canola oil seed meal, the protein concentration is increased to at least about 50 g/L while maintaining the ionic strength substantially constant by using a selective membrane technique. The concentrated protein solution is dried to provide a canola protein isolate having a protein content of at least about 90 wt % (N×6.25) d.b.

Abstract: Provided herein are modified amino acids comprising an azido group, polypeptides, antibodies and conjugates comprising the modified amino acids, and methods of producing the polypeptides, antibodies and conjugates comprising the modified amino acids. The polypeptides, antibodies and conjugates are useful in methods of treatment and prevention, methods of detection and methods of diagnosis.

Abstract: The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.

Abstract: The present invention provides novel, rationally designed lowered affinity antibodies for use in various in vivo and in vitro applications. The antibodies of the present invention have variable domains that have been designed to reduce or eliminate the antigen binding activity of the parental antibody without altering the overall 3 dimensional antibody structure. Using the antibodies of the present invention in various assays allows researchers to distinguish effects that result from specific antigen-antibody interactions from other, non-specific antibody effects.

Abstract: The invention provides single-chain Alphabody library comprising at least 100 different-sequence single-chain Alphabody polypeptides, wherein said Alphabody polypeptides differ from each other in at least one of a defined set of 5 to 20 variegated amino acid residue positions, and wherein at least 70% but not all of said variegated amino acid residue positions are located either in the loop, helix surface or linker region of the Alphabody. The invention further provides methods for use of the Alphabody libraries and Alphabodies obtainable by the methods of the invention.

Abstract: The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.

Abstract: Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Abstract: Disclosed is a use of the CUEDC2 protein in the preparation of diagnostic agents for prognostic determination of the endocrinology therapy for the breast cancer patients and for the diagnosis of tumor such as breast cancer and ovarian cancer. The diagnostic agent comprises an antibody against the CUEDC2 protein, wherein the antibody is a monoclonal or polyclonal antibody against the CUEDC2 protein. Provided is a kit or a composition for prognostic determination of endocrinology therapy for the breast cancer patients and for the diagnosis of tumors such as breast cancer and ovarian cancer. The kit or composition comprises an antibody against the CUEDC2 protein. Further disclosed is a use of the CUEDC2 gene or protein in preparation of drugs for treating tumors, that is, small molecular substances and specific antibodies that specifically inhibit the expression or activity of the CUEDC2 gene\protein are used as a therapeutic agent to restore the sensitivity of drug-resistant tumors to drug treatment.

Abstract: A method for separating a biological conjugate from an aggregate. The molecular weight of the biological conjugate ranges from about 10 kDa to about 1000 kDa. In one embodiment, the method comprises the steps of: (e) providing a mixture comprising the biological conjugate and the aggregate, wherein the biological conjugate has a molecular weight of from about 10 kDa to about 1000 kDa; (f) providing a chromatography column containing a gel, wherein the gel comprises at least one polysaccharide; (g) introducing the mixture of step (a) into the chromatography column; (h) recovering the biological conjugate from the column.

Abstract: The present invention concerns a transformed microalga producing a protein harboring a “high mannose” pattern of glycosylation in the plastid of the transformed microalga, wherein 1) the transformed microalga has a Chloroplast Endoplasmic Reticulum (CER); 2) the microalga has been transformed with a nucleic acid sequence operatively linked to a promoter, the nucleic acid sequence encoding an amino acid sequence including (i) an amino-terminal bipartite topogenic signal (BTS) sequence composed of at least a signal peptide followed by a transit peptide; and (ii) The sequence of the protein, 3) the xylosyltransferases and fucosyltransferases of the microalga have not been inactivated; 4) the N-acetylglycosyltransferase I of the microalga has not been inactivated, preferably the N-acetylglycosyltranferases II, III, IV, V and VI, mannosidase II and glycosyltransferases of the microalga have not been inactivated.

Abstract: The present invention pertains to a method for isolating osteopontin from milk-derived feeds having a high concentration of protein. Particularly, the present method involves the use of a narrow window of pH and specific conductance of the milk-derived feed, which surprisingly has proven to provide a very efficient isolation of osteopontin from chemically complex feeds.

Abstract: The present invention is directed to a method to extract lignin from lignocellulosic biomass using lactic acid.

Abstract: A novel synthesis method of Glyco-drug radiotracer precursor is revealed. After completing synthesis of Z-Gly-ah (main structure), galactosamine GalNAc(OAc)4 is added to have coupling reaction. Then a product is separated directly from dichloromethane. Thus loss of galactosamine during extraction with liquid chromatography is reduced. Moreover, instead of trifluoroacetyl group, carbobenzoxy (abbreviated as Cbz or Z) is used as a protecting group to ensure uniformity of the phase. The cost and synthesis time are also dramatically reduced.

Abstract: The invention provides systems and methods for spatial sequestration of elements in nucleic acid circuits.

Abstract: Amplification primers and methods for specific amplification and detection of a CMV target are disclosed. The primer-target binding sequences are useful for amplification and detection of the CMV target in a variety of amplification and detection reactions.

Abstract: The invention relates to a process for deblocking substantially a blocked, detectably labeled oligonucleotide by contacting the blocked detectably labeled oligonucleotide with an effective amount of a nucleophilic amino compound under conditions that result in substantial deblocking of the oligonucleotide, thereby giving the substantially deblocked oligonucleotide.

Abstract: This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P2Y6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

Abstract: A tumor radiation probe of iodine-123 marker thymidine (FLT) analogue [123I]-IaraU is disclosed. Commercial available uridine is used as the raw material for the synthesis of the precursor. A radioactive iodine-123 is marked on an alkaline group of uridine to obtain [123I]-IaraU, which is distinguishable from [18F]-FLT marking 18F on a glycosyl group to obtain a novel tumor radiation probe. The marking procedures include mixing the marker precursor with Na [123I] solution, acetic acid and hydrogen peroxide solution, and the solution of chloroform and sodium hydroxide. The sonication time increases from 1 minute to 10 minutes, so that [123I]-IaraU has radiologically chemical purity of higher than 98% and radiological specific activity of not less than 0.196 GBq/umole, and the yield can increase from 8% to 40%. Its radioactive specific activity, yield and purity reach to the degree for the use in biological experiments, while reducing production cost.

Abstract: The present invention aims to provide a method of producing a powdered hydrophilic modified polyrotaxane, which enables production of a powdered hydrophilic modified polyrotaxane excellent in storage stability in an industrially advantageous way.

Abstract: The present invention aims to provide a method of producing a hydrophilic modified polyrotaxane, which enables production of a hydrophilic modified polyrotaxane excellent in storage stability in an industrially advantageous way. The present invention provides a method of producing a hydrophilic modified polyrotaxane, comprising: a hydrophilic modification step of preparing a solution of a hydrophilic modified polyrotaxane by modifying all or part of hydroxy groups on a cyclodextrin of a polyrotaxane with hydrophilic modifying groups, the polyrotaxane containing the cyclodextrin, a polyethylene glycol included in the cavities of the cyclodextrin molecules in a skewered manner, and a capping group that is placed at each end of the polyethylene glycol and prevents dissociation of the cyclodextrin molecules from the polyethylene glycol; and a drying step in which the prepared solution of the hydrophilic modified polyrotaxane is formed into a thin film state and dried.

Abstract: [Problem to be Solved] The importance of sugar chains having ?2,3- or ?2,6-linked sialic acid at their non-reducing ends is known. Industrial production has been demanded for these sugar chain compounds. Particularly, the production of glycoprotein drugs or the like inevitably requires producing in quantity sugar chains having homogeneous structures by controlling the linking pattern (?2,6-linkage or ?2,3-linkage) of sialic acid. Particularly, a triantennary or tetraantennary N-type complex sugar chain having sialic acid at each of all non-reducing ends is generally considered difficult to chemically synthesize. There has been no report disclosing that such a sugar chain was chemically synthesized. Furthermore, these sugar chains are also difficult to efficiently prepare enzymatically.

Abstract: The present invention relates to the inhalation delivery of aerosols containing small particles. Specifically, it relates to a method of forming an aerosol for use in inhalation therapy. The method involves: (a) heating a substrate coated with a composition comprising a drug to form a vapor, wherein the coated composition is in the form of a film less than 10 ?thick; and, (b) allowing the vapor to cool, thereby forming an aerosol, which is used in inhalation therapy. In another aspect, a method of forming an aerosol for use in inhalation therapy is provided, wherein the method comprises: (a) heating a substrate coated with a composition comprising a drug to form a vapor in less than 100 milliseconds, wherein the vapor has a mass greater than 0.

Abstract: The present invention relates to a new process for the preparation of a crystalline polymorph of a vasopressin V2 agonist.

Abstract: The present invention relates to purine compounds that are useful as kinase inhibitors. More particularly, the present invention relates to purine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative conditions or disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative conditions or disorders including tumours and cancers as well as other disorders or conditions related to or associated with PI3 and/or mTOR kinases.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Abstract: The present invention relates to compounds of the Formula and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal.

Abstract: The invention provides methods for producing high resolution crystals of ribosomes and ribosomal subunits as well as crystals produced by such methods. The invention also provides high resolution structures of ribosomal subunits either alone or in combination with protein synthesis inhibitors. The invention provides methods for identifying ribosome-related ligands and methods for designing ligands with specific ribosome-binding properties as well as ligands that may act as protein synthesis inhibitors. Thus, the methods and compositions of the invention may be used to produce ligands that are designed to specifically kill or inhibit the growth of any target organism.

Abstract: The present invention is directed to processes for the preparation of substituted pyrimidine derivatives, useful as intermediates in the synthesis of histamine H4 receptor modulators, and to intermediates in H4 modulator synthesis.

Abstract: Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleanine 2,3-dioxygenase (IDO) mediated immunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.

Abstract: The present invention relates to an asymmetric synthesis method of a chiral intermediate (S,S)-2,8-diazabicyclo[4,3,0]nonane (I) of moxifloxacin, wherein an imide or enamine compound is obtained by dehydration reaction of the pyrrolidine-3-ketone as shown in formula (II) and chiral amine(R)-1-phenylethylamine, followed by the reduction of the imide or enamine compound to obtain a compound of formula (III) or (IV) having the chiral structure of formula (I), and then a compound of formula (I) is obtained by intramolecular cyclization, and removal of the chiral auxiliary group and amino-protecting group. The present invention also relates to pyrrolidine-3-ketone as shown in formula (II) and a preparation method therefor, and in the formula (I), (II), (III), (IV), R is an amino-protecting group, especially C1-4 alkoxycarbonyl, benzyloxycarbonyl or benzyl which can be removed by hydrolysis or hydrogenation.

Abstract: Polyphenylene compounds such as compounds represented by Formulas 1-28 may be used in electronic devices such as organic light-emitting devices. For example, the compounds may be used as host material in an emissive layer.

Abstract: Synthesis of platinum(II) di(2-pyrazolyl)benzene chloride and analogs includes forming a 1,3-di-substituted benzene including two aromatic five-membered heterocycles, and reacting the 1,3-di-substituted benzene with an acidic platinum-containing solution to form a luminescent platinum(II) complex. The luminescent platinum(II) complex is capable of emitting blue and white light and can be used as an emitter in a light emitting device.

Abstract: Aromatic azole compounds such as 2-(4-aminophenyl)-5-amino-benzimidazole are prepared in an organic sulfonic acid solvent instead of polyphosphoric acid. This allows recovery and recycle of the solvent and avoids the handling and environmental concerns resulting from the use of polyphosphoric acid. The resulting compounds find use in the pharmaceutical industry, as anticorrosion agents, and as precursors for high-performance fibers having high strength, stiffness, and flame resistance.